Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
Vanda Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Vanda Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $122.02M, up 21.9% year over year. For fiscal 2025 it was $109.27M, up 46.8% from the year before. Over ten years it grew 14.1% a year on average. The highest annual figure on record is $109.27M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.27M | +46.8% |
| FY2024 | Dec 31, 2024 | $74.43M | -3.1% |
| FY2023 | Dec 31, 2023 | $76.82M | -10.4% |
| FY2022 | Dec 31, 2022 | $85.77M | +13.8% |
| FY2021 | Dec 31, 2021 | $75.36M | +35.6% |
| FY2020 | Dec 31, 2020 | $55.58M | +14.2% |
| FY2019 | Dec 31, 2019 | $48.65M | +11.6% |
| FY2018 | Dec 31, 2018 | $43.59M | +13.1% |
| FY2017 | Dec 31, 2017 | $38.55M | +32.2% |
| FY2016 | Dec 31, 2016 | $29.16M | +0.0% |
| FY2015 | Dec 31, 2015 | $29.15M | +51.6% |
| FY2014 | Dec 31, 2014 | $19.23M | -32.5% |
| FY2013 | Dec 31, 2013 | $28.50M | -37.7% |
| FY2012 | Dec 31, 2012 | $45.76M | +57.8% |
| FY2011 | Dec 31, 2011 | $29.00M | +135.0% |
| FY2010 | Dec 31, 2010 | $12.34M | -11.1% |
| FY2009 | Dec 31, 2009 | $13.87M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $27.62M | +22.4% |
| Q2 FY2026 | Jun 30, 2026 | $36.95M | +68.0% |
| Q1 FY2026 | Mar 31, 2026 | $28.44M | -20.4% |
| Q4 FY2025 | Dec 31, 2025 | $29.01M | +46.2% |
| Q3 FY2025 | Sep 30, 2025 | $22.56M | +34.5% |
| Q2 FY2025 | Jun 30, 2025 | $21.99M | +32.0% |
| Q1 FY2025 | Mar 31, 2025 | $35.71M | +68.8% |
| Q4 FY2024 | Dec 31, 2024 | $19.84M | -18.5% |
| Q3 FY2024 | Sep 30, 2024 | $16.78M | +1.1% |
| Q2 FY2024 | Jun 30, 2024 | $16.66M | +0.1% |
| Q1 FY2024 | Mar 31, 2024 | $21.15M | +10.0% |
| Q4 FY2023 | Dec 31, 2023 | $24.34M | +31.9% |
| Q3 FY2023 | Sep 30, 2023 | $16.60M | -33.2% |
| Q2 FY2023 | Jun 30, 2023 | $16.65M | -22.5% |
| Q1 FY2023 | Mar 31, 2023 | $19.24M | -8.3% |
| Q4 FY2022 | Dec 31, 2022 | $18.45M | -4.5% |
| Q3 FY2022 | Sep 30, 2022 | $24.86M | +26.5% |
| Q2 FY2022 | Jun 30, 2022 | $21.49M | +6.1% |
| Q1 FY2022 | Mar 31, 2022 | $20.97M | +30.0% |
| Q4 FY2021 | Dec 31, 2021 | $19.33M | +30.2% |
| Q3 FY2021 | Sep 30, 2021 | $19.65M | +59.8% |
| Q2 FY2021 | Jun 30, 2021 | $20.25M | +56.9% |
| Q1 FY2021 | Mar 31, 2021 | $16.13M | +3.9% |
| Q4 FY2020 | Dec 31, 2020 | $14.85M | +13.6% |
| Q3 FY2020 | Sep 30, 2020 | $12.30M | +8.4% |
| Q2 FY2020 | Jun 30, 2020 | $12.90M | +17.8% |
| Q1 FY2020 | Mar 31, 2020 | $15.53M | +16.9% |
| Q4 FY2019 | Dec 31, 2019 | $13.07M | +1.2% |
| Q3 FY2019 | Sep 30, 2019 | $11.35M | -0.4% |
| Q2 FY2019 | Jun 30, 2019 | $10.95M | +11.0% |
| Q1 FY2019 | Mar 31, 2019 | $13.28M | +41.0% |
| Q4 FY2018 | Dec 31, 2018 | $12.92M | +27.3% |
| Q3 FY2018 | Sep 30, 2018 | $11.39M | +11.9% |
| Q2 FY2018 | Jun 30, 2018 | $9.87M | +29.0% |
| Q1 FY2018 | Mar 31, 2018 | $9.42M | -10.9% |
| Q4 FY2017 | Dec 31, 2017 | $10.15M | +33.4% |
| Q3 FY2017 | Sep 30, 2017 | $10.18M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.65M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.57M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.61M | – |
See a number that looks wrong?